Ontology highlight
ABSTRACT:
SUBMITTER: Ball DW
PROVIDER: S-EPMC4583528 | biostudies-literature | 2015 Nov
REPOSITORIES: biostudies-literature
Ball Douglas W DW Jin Ning N Xue Ping P Bhan Sheetal S Ahmed Shabina R SR Rosen D Marc DM Schayowitz Adam A Clark Douglas P DP Nelkin Barry D BD
Oncology reports 20150826 5
Multikinase inhibitors (MKIs) targeting VEGF receptors and other receptor tyrosine kinases have shown considerable activity in clinical trials of thyroid cancer. Thyroid cancer frequently exhibits activation of the RAS/RAF/MEK/ERK pathway. In other types of cancer, paradoxical ERK activation has emerged as a potential resistance mechanism to RAF-inhibiting drugs including MKIs such as sorafenib and pazopanib. We therefore queried whether the MEK inhibitor trametinib, could augment the activity o ...[more]